Recently, Guangyao Baiyunshan released its 2020 financial report, which showed that the company achieved revenue of 61.674 billion yuan. Among them, the company's "ace", Pink Jinge, made a great contribution to the performance and was sold in one year. With nearly 80 million pieces, Baiyunshan Jin Ge has once again become a hot search topic.
On March 23, GPHL signed a strategic cooperation agreement with Tsinghua Pearl River Delta Research Institute, a national industry-university-research cooperation platform and the "locomotive" of technological innovation in the Guangdong-Hong Kong-Macao Greater Bay Area. Baiyunshan Pharmaceutical General Factory, a leading innovative enterprise, will work with Tsinghua Pearl River Delta Research Institute to build a technological innovation incubation system and industrial investment platform.
Independently research and develop the first generic drug to break the monopoly of foreign investment
Baiyunshan currently has three main business sectors, namely Great Southern Medicine, Great Health and Great Commerce. Among them, one of the core backbones of Southern Medicine is the generic drug of sildenafil citrate "Jin Ge". This product is the first generic drug independently developed by Baiyunshan Pharmaceutical Factory after 16 years of painstaking efforts. It embodies the efforts of Baiyunshan Pharmaceutical Factory’s high-end scientific research team and has high quality that is completely biologically equivalent to the original product. The launch of this product also broke the 13-year market monopoly of foreign-funded enterprises in the domestic ED drug market.
In 2020, Jinge sold 78.3452 million pieces, with sales increasing by 26.86% year-on-year, and revenue increasing by 10.6% year-on-year to 833 million yuan.
In fact, Jinge has been widely recognized by the market since its launch in 2014, and its market sales and market share have increased year by year: from 2017 to 2019, this product has ranked among Tmall's "Double 11" drug transactions for three consecutive years. Top of the list; according to Minenet data, its sales volume in 2018 was more than twice that of the original product, accounting for 66.85%, making it the TOP1 ED sales brand; in 2019, its market share and market share ranked first; last year, Jin All three product specifications of Jinge took the lead in passing the national generic drug consistency evaluation, which further boosted Jinge's domestic market share and sales.
"Compared with the same category, this product is of high quality and low price. It has completely bioequivalent quality to the original research product, but it is launched at a price that reduces the cost of a single dose by nearly 60%, effectively reducing the cost. According to the person in charge of Guangzhou Pharmaceutical Group Baiyunshan Pharmaceutical Factory, the company has also made innovations in marketing methods, integrating them with fashion and being down-to-earth to further expand the market. For example, in recent years, the company has interacted with fans through its official WeChat, created the character "Jin Ge", spread and popularized men's health knowledge, attracted the attention of many young people, and the consumer group has continued to expand. It has successively established the Baiyunshan Jinge Pulmonary Artery Hypertension Charity Assistance Project with Beijing Aixike, Zhong Nanshan Foundation and other public welfare organizations. It has invested millions of yuan in total to accurately support pulmonary hypertension patients with financial difficulties who are suitable for taking Jinge and expand the pulmonary hypertension drug market.
Baiyunshan Pharmaceutical General Factory is known as the "innovation gene"
Over the years, GPHL has continuously promoted its subsidiaries and R&D teams to keep up with the market, and continuously forced scientific research and innovation according to market demand. , and conduct basic research in the medical field to create its own competitive "moat." Among them, Baiyunshan Pharmaceutical Factory is the "scientific research leader" of GPHL. Over the years, it has performed well in innovative research results.
In addition to Jinge, Baiyunshan Pharmaceutical General Factory has also developed the first domestic cephalosporin with independent intellectual property rights - cefathiamidine, and successfully obtained clinical approval for the Class 1.1 new drug ceftriazida sodium. It has filled the gap in the approval of new cephalosporin class 1.1 drugs in my country in the past 20 years.
Since 2020, the factory has signed new drug strategic cooperation agreements with WuXi AppTec, Chengdu HitGen, etc., in the field of small molecule innovative drug research and development, key core technology research, scientific and technological achievement transformation platform, and new drug research and development. In terms of cooperation, we will build multi-dimensional cooperation models and areas of cooperation.
On March 23 this year, GPHL signed a strategic cooperation agreement with Tsinghua Pearl River Delta Research Institute, a national industry-university-research cooperation platform and the "locomotive" of technological innovation in the Guangdong-Hong Kong-Macao Greater Bay Area. Baiyunshan Pharmaceutical As a pilot enterprise, the main factory will work with Tsinghua Pearl River Delta Research Institute to build a scientific and technological innovation incubation system and industrial investment platform, absorb high-level talents and social capital more broadly, form an empowered platform ecosystem, and incubate the transformation of a number of new drug project results. .
In addition, it is reported that the R&D team of Baiyunshan Pharmaceutical Factory has completed emergency scientific research on remdesivir and has now mastered the key technology of injectable remdesivir, a drug with potential to treat the new coronavirus.
Remdesivir is a broad-spectrum antiviral drug and a potential drug for the treatment of Covid-19. It was first developed for Ebola virus and is used for SARS and Middle East Respiratory Syndrome, which are also coronaviruses. Symptoms and other diseases.
This year is the first year of my country's "14th Five-Year Plan". According to the strategic layout of GPHL, it will further increase scientific and technological innovation, accelerate the pace of innovation and development, and create a unique industry with unique industrial characteristics and distinctive culture. A world-class biopharmaceutical and health enterprise. As the "backbone" of the group's scientific research and innovation, Baiyunshan Pharmaceutical General Factory will also play a more important role.